Rivaroxaban for the treatment of venous thromboembolism in real life

Abstract

The clinical profile, evolution and complications of treatment with rivaroxaban in a cohort of patients presenting with venous thromboembolism (VTE) were analyzed in an observational, non-interventional and prospective study.A total of 111 patients were included in the study. Clinical data were collected from the medical history of the patients and recorded in a specific database.Mean age was 63.8 ± 17.4 years, 53.2% of patients were men, 55.9% had at least another concomitant condition, and 40.9% at least 1 VTE risk factor. 54.1% of patients presented with deep venous thrombosis, 32.4% with pulmonary embolism and 13.5% with both conditions simultaneously. The 61% of patients were admitted to hospital and mean hospital length-of-stay was 8.8 ± 9.9 days. After a mean follow-up 530 ± 464 days (median follow-up of 405 days), 3.9% of patients died and VTE recurrence occurred in 2.9% of patients. While receiving rivaroxaban, a first bleeding complication occurred in 8.1%; all events were minor bleeding.Our study supports the current literature data and confirms the similar results of real-life VTE patients with those enrolled in the rivaroxaban pivotal clinical trials. Rivaroxaban may facilitate outpatient treatment and might be considered as a first-line therapy for the management of VTE patients.

Analysis of Drug Compliance among Patients Suffering from Deep Vein Thrombosis

“…In current research overall drug compliance with antithrombotic drugs was reported in 296 (77.1%) DVT patients, A similar study by Kang, J. M., et al, reported the overall drug compliance 93.8% with antithrombotic drugs [23].…”

“…In current research mean age of DVT patients was 43.78 ± 12.43 [23]. Another study by Demelo-Rodríguez, P., et al, also reported the hypertension in 43.2% DVT patients, DM in 11.7% DVT patients and ischemic heart disease in 7.2% DVT patients [24].…”

Magnetic coagulometry: towards a new nanotechnological tool for ex vivo monitoring coagulation in human whole blood

“…Direct oral anticoagulants (DOAC) like rivaroxaban were designed to reduce the need of frequent coagulation monitoring in patients 42 suffering from conditions like atrial fibrillation, 43 coronary heart disease 44 and VTE, 45 as well as those in need of thromboprophylaxis. 46 However, monitoring of blood coagulation is still required for a number of demographic groups taking these drugs.…”